News

Patent broadly covers RNA-based oligonucleotide therapeutics such as a RNA duplex, a microRNA mimic, a microRNA antagonist and a RNA-binding RNA steric blocker containing a UNA. The RNA

Epigenomics chief financial officer and acting chief executive officer Thomas Taapken said based on the achieved non-inferiority in CRC detection, the company believes that Epi proColon has demonstrated

The new patent entitled Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy provides protection until December 2019. Jazz Pharmaceuticals chairman and chief executive

TTC transactions operations director Brandon Fitzgerald said TTC is pleased to close the transaction for UCH, who had built a local business that served community for almost two

Vertigo occurs more in women ages 50-60 or the elderly with debilitating symptoms including dizziness, nausea, disorientation, and a spinning sensation. Vertigo, in general, is treated with prescription

Using its new office, Essex Woodlands will assist Chinese entrepreneurs to construct companies in all sectors of the Chinese healthcare industry. Shanghai office co-managing director David Yang said,

According to the agreement, Teva Israel will be responsible for regulatory registration and commercialization activities of the product in the region besides funding for local development. Galena is

The drugs are indicated for pharyngitis, nasopharynx, gastroenteropathy, nephropathy, asthma, hyperplasia of mammary glands, dermatosis, gynecological diseases, etc. Biostar chief executive officer and chairman Ronghua Wang said the

The PJ-01 development project will leverage Parabon’s Essemblix drug development platform to design macromolecules and nanoscale fabrication technology used in the production. The NSF grant program funds technology